<p>Adverum Biotechnologies, Inc.（納斯達克代碼：ADVM - 獲取免費報告）首席運營官 Peter Soparkar 於 12 月 5 日（星期五）購買了 50,000 股該公司的股票。該股票的平均購買成本為每股 4.22 美元，總交易額為 211,000.00 美元。收購後，首席運營官持有該公司 80,189 股股票，估值約為 338,397.58 美元。這筆交易代表了其持股比例的 165.62% 的增長。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，相關文件可通過此鏈接獲取。</p>
<h2>Adverum Biotechnologies 股票上漲 2.3%</h2>
<p>在週一的午盤交易中，納斯達克 ADVM 的股票上漲了 0.10 美元，達到了 4.36 美元。該公司交易了 987,543 股，相比之下，其平均交易量為 447,123 股。該股票的 50 日簡單移動平均為 4.41 美元，200 日簡單移動平均為 3.35 美元。Adverum Biotechnologies, Inc.的 1 年最低價為 1.78 美元，1 年最高價為 6.12 美元。該公司的市值為 9626 萬美元，市盈率為-0.51，貝塔值為 0.87。</p>
<p>Adverum Biotechnologies（納斯達克：ADVM - 獲取免費報告）最近於 11 月 12 日（星期三）公佈了季度財報。這家生物技術公司報告本季度每股收益（EPS）為-2.03 美元，低於分析師一致預期的-1.80 美元，差距為 0.23 美元。分析師預計 Adverum Biotechnologies, Inc.在本財年的每股收益將為-4.92 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票分析師對該公司發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Adverum Biotechnologies 股票的 “賣出（d-）” 評級。Truist Financial 在 10 月 24 日（星期五）的研究報告中設定了 Adverum Biotechnologies 股票的目標價為 5.00 美元。Chardan Capital 在 10 月 27 日（星期一）的研究報告中將 Adverum Biotechnologies 的評級從 “強烈買入” 下調至 “持有”。Mizuho 在 10 月 29 日（星期三）的研究報告中設定了 Adverum Biotechnologies 的目標價為 5.50 美元。最後，HC Wainwright 在 11 月 17 日（星期一）的報告中重新發布了 “中性” 評級，並將 Adverum Biotechnologies 的目標價設定為 5.00 美元（之前為 30.00 美元）。一位分析師給予該股票 “買入” 評級，四位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，Adverum Biotechnologies 目前的共識評級為 “持有”，平均目標價為 10.50 美元。</p>
<p><strong>閲讀我們對 Adverum Biotechnologies 的最新股票分析</strong></p>
<h2>Adverum Biotechnologies 的機構交易</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。BML Capital Management LLC 在第二季度將其在 Adverum Biotechnologies 的持股增加了 11.5%。BML Capital Management LLC 目前擁有 3,057,526 股該生物技術公司的股票，價值 6,574,000 美元，此前在上個季度又收購了 315,209 股。Pale Fire Capital SE 在第一季度將其在 Adverum Biotechnologies 的持股增加了 16.9%。Pale Fire Capital SE 目前擁有 368,267 股該生物技術公司的股票，價值 1,609,000 美元，此前在上個季度又收購了 53,113 股。Two Sigma Investments LP 在第三季度將其在 Adverum Biotechnologies 的持股增加了 372.7%。Two Sigma Investments LP 目前擁有 88,670 股該生物技術公司的股票，價值 402,000 美元，此前在此期間又購買了 69,913 股。Jane Street Group LLC 在第二季度收購了 Adverum Biotechnologies 的新頭寸，價值約為 153,000 美元。最後，Invesco Ltd.在第一季度收購了 Adverum Biotechnologies 的新頭寸，價值約為 218,000 美元。對沖基金和其他機構投資者持有該公司 48.17% 的股票。</p>
<h2>關於 Adverum Biotechnologies</h2>
<p>（獲取免費報告）</p>
<p>Adverum Biotechnologies, Inc.是一家臨牀階段公司，開發基因治療產品候選藥物以治療眼科疾病。其主要產品候選藥物是 ixoberogene soroparvovec（ADVM-022），這是一種用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的單次玻璃體內注射基因治療候選藥物，目前處於二期臨牀試驗階段。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Adverum Biotechnologies</li>
<li>基礎材料股票投資</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
<li>百分比漲幅告訴投資者什麼，以及為什麼它們並沒有告訴全部故事</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Adverum Biotechnologies 嗎？</h2>
<p>在你考慮 Adverum Biotechnologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Adverum Biotechnologies 並不在名單上。</p>
<p>雖然 Adverum Biotechnologies 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Adverum生物科技

<p>Adverum 生物科技的首席運營官 Peter Soparkar 購買了 50,000 股公司股票，花費 211,000 美元，使他的持股增加了 165.62%。此次股票購買在 SEC 文件中披露。交易後，Soparkar 持有 80,189 股，價值約 338,398 美元。公司的股票上漲了 2.3%，至 4.36 美元。分析師對該股票的評級不一，普遍評級為 “持有”，平均目標價為 10.50 美元。機構投資者持有公司 48.17% 的股票</p>

<p>Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) COO Peter Soparkar bought 50,000 shares of the company's stock in a transaction dated Friday, December 5th. The stock was bought at an average cost of $4.22 per share, for a total transaction of $211,000.00. Following the acquisition, the chief operating officer owned 80,189 shares of the company's stock, valued at approximately $338,397.58. This trade represents a 165.62% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>Adverum Biotechnologies, Inc.（納斯達克代碼：ADVM - 獲取免費報告）首席運營官 Peter Soparkar 於 12 月 5 日（星期五）購買了 50,000 股該公司的股票。該股票的平均購買成本為每股 4.22 美元，總交易額為 211,000.00 美元。收購後，首席運營官持有該公司 80,189 股股票，估值約為 338,397.58 美元。這筆交易代表了其持股比例的 165.62% 的增長。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，相關文件可通過此鏈接獲取。</p>
</div><h2>Adverum Biotechnologies Stock Up 2.3%</h2>
<div class="lb-trans"><h2>Adverum Biotechnologies 股票上漲 2.3%</h2>
</div><p>Shares of NASDAQ ADVM traded up $0.10 during mid-day trading on Monday, hitting $4.36. 987,543 shares of the company were exchanged, compared to its average volume of 447,123. The stock has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $3.35. Adverum Biotechnologies, Inc. has a 1-year low of $1.78 and a 1-year high of $6.12. The firm has a market cap of $96.26 million, a price-to-earnings ratio of -0.51 and a beta of 0.87.</p>
<div class="lb-trans"><p>在週一的午盤交易中，納斯達克 ADVM 的股票上漲了 0.10 美元，達到了 4.36 美元。該公司交易了 987,543 股，相比之下，其平均交易量為 447,123 股。該股票的 50 日簡單移動平均為 4.41 美元，200 日簡單移動平均為 3.35 美元。Adverum Biotechnologies, Inc.的 1 年最低價為 1.78 美元，1 年最高價為 6.12 美元。該公司的市值為 9626 萬美元，市盈率為-0.51，貝塔值為 0.87。</p>
</div><p>Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.80) by ($0.23). Analysts anticipate that Adverum Biotechnologies, Inc. will post -4.92 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Adverum Biotechnologies（納斯達克：ADVM - 獲取免費報告）最近於 11 月 12 日（星期三）公佈了季度財報。這家生物技術公司報告本季度每股收益（EPS）為-2.03 美元，低於分析師一致預期的-1.80 美元，差距為 0.23 美元。分析師預計 Adverum Biotechnologies, Inc.在本財年的每股收益將為-4.92 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities analysts have issued reports on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adverum Biotechnologies in a research report on Wednesday, October 8th. Truist Financial set a $5.00 price target on shares of Adverum Biotechnologies in a research report on Friday, October 24th. Chardan Capital downgraded Adverum Biotechnologies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Mizuho set a $5.50 target price on Adverum Biotechnologies in a research report on Wednesday, October 29th. Finally, HC Wainwright reissued a &#34;neutral&#34; rating and issued a $5.00 target price (down previously from $30.00) on shares of Adverum Biotechnologies in a report on Monday, November 17th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Adverum Biotechnologies presently has a consensus rating of &#34;Hold&#34; and an average target price of $10.50.</p>
<div class="lb-trans"><p>幾位股票分析師對該公司發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Adverum Biotechnologies 股票的 “賣出（d-）” 評級。Truist Financial 在 10 月 24 日（星期五）的研究報告中設定了 Adverum Biotechnologies 股票的目標價為 5.00 美元。Chardan Capital 在 10 月 27 日（星期一）的研究報告中將 Adverum Biotechnologies 的評級從 “強烈買入” 下調至 “持有”。Mizuho 在 10 月 29 日（星期三）的研究報告中設定了 Adverum Biotechnologies 的目標價為 5.50 美元。最後，HC Wainwright 在 11 月 17 日（星期一）的報告中重新發布了 “中性” 評級，並將 Adverum Biotechnologies 的目標價設定為 5.00 美元（之前為 30.00 美元）。一位分析師給予該股票 “買入” 評級，四位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，Adverum Biotechnologies 目前的共識評級為 “持有”，平均目標價為 10.50 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Adverum Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Adverum Biotechnologies 的最新股票分析</strong></p>
</div><h2>Institutional Trading of Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>Adverum Biotechnologies 的機構交易</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC increased its stake in shares of Adverum Biotechnologies by 11.5% during the 2nd quarter. BML Capital Management LLC now owns 3,057,526 shares of the biotechnology company's stock valued at $6,574,000 after acquiring an additional 315,209 shares during the last quarter. Pale Fire Capital SE boosted its position in shares of Adverum Biotechnologies by 16.9% in the first quarter. Pale Fire Capital SE now owns 368,267 shares of the biotechnology company's stock worth $1,609,000 after acquiring an additional 53,113 shares during the last quarter. Two Sigma Investments LP grew its holdings in Adverum Biotechnologies by 372.7% in the third quarter. Two Sigma Investments LP now owns 88,670 shares of the biotechnology company's stock valued at $402,000 after purchasing an additional 69,913 shares during the period. Jane Street Group LLC acquired a new position in Adverum Biotechnologies during the second quarter worth approximately $153,000. Finally, Invesco Ltd. purchased a new position in Adverum Biotechnologies during the first quarter worth approximately $218,000. Hedge funds and other institutional investors own 48.17% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。BML Capital Management LLC 在第二季度將其在 Adverum Biotechnologies 的持股增加了 11.5%。BML Capital Management LLC 目前擁有 3,057,526 股該生物技術公司的股票，價值 6,574,000 美元，此前在上個季度又收購了 315,209 股。Pale Fire Capital SE 在第一季度將其在 Adverum Biotechnologies 的持股增加了 16.9%。Pale Fire Capital SE 目前擁有 368,267 股該生物技術公司的股票，價值 1,609,000 美元，此前在上個季度又收購了 53,113 股。Two Sigma Investments LP 在第三季度將其在 Adverum Biotechnologies 的持股增加了 372.7%。Two Sigma Investments LP 目前擁有 88,670 股該生物技術公司的股票，價值 402,000 美元，此前在此期間又購買了 69,913 股。Jane Street Group LLC 在第二季度收購了 Adverum Biotechnologies 的新頭寸，價值約為 153,000 美元。最後，Invesco Ltd.在第一季度收購了 Adverum Biotechnologies 的新頭寸，價值約為 218,000 美元。對沖基金和其他機構投資者持有該公司 48.17% 的股票。</p>
</div><h2>About Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>關於 Adverum Biotechnologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.</p>
<div class="lb-trans"><p>Adverum Biotechnologies, Inc.是一家臨牀階段公司，開發基因治療產品候選藥物以治療眼科疾病。其主要產品候選藥物是 ixoberogene soroparvovec（ADVM-022），這是一種用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的單次玻璃體內注射基因治療候選藥物，目前處於二期臨牀試驗階段。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Adverum Biotechnologies</li>
<li>Basic Materials Stocks Investing</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Adverum Biotechnologies</li>
<li>基礎材料股票投資</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
<li>百分比漲幅告訴投資者什麼，以及為什麼它們並沒有告訴全部故事</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ADVM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adverum Biotechnologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Adverum Biotechnologies 嗎？</h2>
</div><p>Before you consider Adverum Biotechnologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Adverum Biotechnologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Adverum Biotechnologies 並不在名單上。</p>
</div><p>While Adverum Biotechnologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adverum Biotechnologies 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Adverum 生物科技（NASDAQ:ADVM）的首席運營官購買了價值 211,000 美元的股票